

5 JUNE 2014, 5 :35 PM CET

Cardio3 BioSciences nominated for the European Mediscience Awards 2014

Mont-Saint-Guibert, Belgium, - The Belgian biotechnology company Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris : CARD), leader in the discovery and development of advanced regenerative therapies for heart disease, is pleased to announce that it has been short listed for two 2014 European Mediscience Awards, the “Breakthrough Award” and “The Best Technology Award” .

The European Mediscience Awards is the premier event for all stakeholders of the European mediscience sector and celebrates outstanding achievement of both public and private companies in the healthcare, biotech and life science sectors.

Cardio3 BioSciences’ most advanced therapy, C-Cure® is being developed as a treatment for heart failure and consists of a patient’s own cells that are harvested from the patient’s bone marrow and engineered to regenerate the heart. This process is known as Cardiopoiesis. C-Cure® is in a Phase III clinical trial in Europe. The trial, called CHART-1, represents the world’s first Phase III trial for a pre-programmed cellular therapy targeting heart failure. C-Cure® builds on research conducted at Mayo Clinic (Rochester, Minnesota, USA), Cardio3 BioSciences (Mont-Saint-Guibert, Belgium) and Cardiovascular Centre Aalst (Aalst, Belgium).

Dr Christian Homsy, CEO of Cardio3 BioSciences, comments: “We are very proud and honored to have been nominated for two 2014 European Mediscience Awards. We have been developing our breakthrough approach to heart failure for many years with the goal to profoundly improve quality of life for patients and their families. These nominations recognize the progress we have made, together with other players in regenerative medicine, towards inventing a new industry, a new medical approach and in bringing new hope for patients.”

*** END ***

For more information contact:

Cardio3 BioSciences

Dr Christian Homsy, CEO

Anne Portzenheim, Communication Manager

www.c3bs.com

Tel : +32 10 39 41 00

aportzenheim@c3bs.com

Citigate Dewe Rogerson

Chris Gardner

Tel : +44 (0) 207 638 9571

5 JUNE 2014, 5 :35 PM CET

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the USA and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure[®] is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure[®] consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to regenerate the heart. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath_{ez}[®], the most technologically injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.
